Enas M Kamal (E M Kamal)

Publication Activity (10 Years)

Years Active: 2018-2019
Publications (10 Years): 4

Top Topics

Mesenchymal Stem Cells

Randomized Controlled Trial

Replacement Therapy

Top Venues

Alimentary pharmacology & therapeutics

Liver international : official journal of the International Association for the Study of the Liver

This page only lists publications with an associated author ORCID identifier.

Publications

Enas M Kamal, Mortada El-Shabrawi, Hisham El-Khayat, Naglaa M. Kamal, Yehia Sameh, Yasser Fouad, Dina Attia
Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. Liver international : official journal of the International Association for the Study of the Liver 40 (2) (2019)
H El-Khayat, Y Fouad, H I Mohamed, H El-Amin, Enas M Kamal, M Maher, A Risk
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Alimentary pharmacology & therapeutics 47 (5) (2018)
H R El-Khayat, Enas M Kamal, M H El-Sayed, M El-Shabrawi, H Ayoub, A RizK, M Maher, R Y El Sheemy, Y M Fouad, Dina Attia
The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Alimentary pharmacology & therapeutics 47 (6) (2018)
M H F El-Shabrawi, Naglaa M Kamal, H R El-Khayat, Enas M Kamal, M M A H AbdElgawad, Naglaa M. Kamal
A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children. Alimentary pharmacology & therapeutics 47 (12) (2018)